| Literature DB >> 31408294 |
Demet Bölükbaşı1, Alev Şaylan2, Sema Turan1, Sultan Sevim Yakın1, Dilek Kazancı1, Ayşegül Özgök3, Hija Yazıcıoğlu3.
Abstract
Background/aim: Cardiac surgery, especially in the presence of cardiopulmonary bypass (CPB), is associated with an inflammatory reaction that may promote microcirculatory alterations, in addition to the general impact on system hemodynamics. Anemia and transfusion make patients more susceptible to the deleterious effects of CPB. In this study, it was aimed to evaluate the effect of dilutional anemia, which is caused by CPB and can be treated with 1–2 units of red blood cell (RBC) transfusion, on global tissue oxygenation parameters in cardiac surgery patients. Materials and methods: This prospective observational study comprised 127 patients who had a relatively stable operation period without any major anesthetic or surgical complications (e.g., operation duration >5 h, bleeding or hemodilution requiring more than 1–2 units of RBCs, or unstable hemodynamics, requiring inotropic support of more than 5 μg/kg/min dopamine). Patients were observationally divided into two groups: minimally transfused (Group Tr) and nontransfused (Group NTr). Global tissue oxygenation parameters were evaluated after anesthesia induction (T1) and at the end of the operation (T3) and compared between the groups.Entities:
Keywords: Cardiac surgical procedures; blood transfusion; microcirculation; lactate; arteriovenous carbon dioxide difference
Mesh:
Year: 2019 PMID: 31408294 PMCID: PMC7018202 DOI: 10.3906/sag-1901-213
Source DB: PubMed Journal: Turk J Med Sci ISSN: 1300-0144 Impact factor: 0.973
Patient characteristics.
| Group NTr(n = 102) | Group Tr(n = 25) | P | |
| Sex, female/male | 26/76 (25.5/74.5) | 9/16 (36.0/64.0) | 0.293 |
| Age, years | 57.9 ± 9.4 | 61.04 ± 10.6 | 0.156 |
| Body surface area, m2 | 1.81 ± 0.4 | 1.83 ± 0.5 | 0.347 |
| Preoperative hemoglobin, g/dL | 14.4 ± 1.3 | 13.1 ± 1.0 | 0.000 |
| Comorbidities HT | 30 (29.4) | 7 (28.0) | 0.472 |
| DM | 10 (9.8) | 2 (8.0) | 0.164 |
| Preoperative medications Beta-blockers | 42 (41.7) | 11 (44.0) | 0.184 |
| ACEI | 14 (13.7) | 4 (16.0) | 0.234 |
| Diuretics | 9 (4.08) | 1 (4.0) | 0.782 |
| ARA | 11 (10.78) | 2 (8.0) | 0.487 |
| CCB | 9 (8.32) | 2 (8.0) | 0.286 |
| Statin | 44 (43.13) | 10 (40.0) | 0.126 |
| OAD | 14 (13.72) | 4 (16.0) | 0.232 |
Data are presented as n (%) or mean ± SD. HT: Hypertension, DM: diabetes mellitus, ACEI: angiotensin-converting enzyme inhibitor, ARA: aldosterone receptor antagonist, CCB: calcium channel blocker, OAD: oral antidiabetic agents.
Operative variables.
| Group NTr (n = 102) | Group Tr(n = 25) | P | |
| Type of operation CABG surgery | 82 (80.4) | 20 (80) | 1.000 |
| Valvular surgery | 20 (19.6) | 5 (20) | |
| Operation duration (min) | 254.6 ± 45.8 | 265.8 ± 36.5 | 0.387 |
| Perfusion duration (min) | 92.9 ± 26.0 | 96.6 ± 20.8 | 0.606 |
| Cross clamp duration (min) | 63.6 ± 23.0 | 67.8 ± 20.0 | 0.447 |
Data are presented as n (%) or the mean ± SD.
Hemoglobin values measured in both groups (g/dL).
| Groups | T1 (before skin incision) | T2 (fifth min of CPB) | T3 (after skin closure) | P (within groups) |
| Group NTr | 13.3 ± 1.5 (13.4; 9.6–16.9) | 8.7 ± 1.4(8.6; 7.1–12.9) | 9.4 ± 1.1(9.2; 7.8–12.4) | 0.000 |
| Group Tr | 11.9 ± 1.3(12.1; 9.6–16.3) | 6.6 ± 0.3(6.7; 6.1–6.9) | 9.0 ± 0.9(8.9; 8.1–11.4) | 0.000 |
| P (between groups) | 0.000 | 0.000 | 0.082 | - |
Data are presented as the mean ± SD (median; min–max).
Tissue oxidation parameters (ΔpCO2, ScvO2, and lactate) measured in both groups.
| T1 (before skin incision) | T3 (after skin closure) | P (within groups) | |
| ΔpCO2 (mmHg)Group NTr | 6.1 ± 2.8 (6.1; 0.1–14.5) | 6.1 ± 3.4 (6.0; 0.4–20.3) | 0.929 |
| Group Tr | 4.9 ± 2.9 (5.2; 0.8–10.1) | 8.8 ± 7.1 (7.4; 0.8–31.9) | 0.018 |
| Total | 5.8 ± 2.8 (5.8; 0.1–14.5) | 6.6 ± 4.5 (6.2; 0.4–31.9) | 0.264 |
| P (between groups) | 0.073 | 0.057 | - |
| ScvO2 (%)Group NTr | 73.2 ± 9.0 (74.5; 45.5–89.8) | 64.3 ± 9.6 (63.0; 36.8–85.0) | 0.000 |
| Group Tr | 71.9 ± 10.1 (71.7; 54.0–88.8) | 62.3 ± 9.7 (62.0; 40.4–79.6) | 0.003 |
| Total | 72.9 ± 9.2 (73.9; 45.5–89.8) | 63.9 ± 9.6 (62.7; 36.8–85.0) | 0.000 |
| P (between groups) | 0.522 | 0.371 | - |
| Lactate (mmol/L)Group NTr | 1.1 ± 0.5 (1.0; 0.2–2.7) | 2.2 ± 1.1 (2.0; 0.7–5.6) | 0.000 |
| Group Tr | 1.0 ± 0.3 (1.0; 0.6–1.8) | 2.9 ± 1.6 (2.1; 0.9–7.0) | 0.000 |
| Total | 1.0 ± 0.4 (1.0; 0.2–2.7) | 2.3 ± 1.2 (2.0; 0.7–7.0) | 0.000 |
| P (between groups) | 0.566 | 0.009 | - |
Data are presented as mean ± SD (median; min–max).
Increment rates of ΔpCO2, ScvO2, and lactate (T3–T1 /T1).
| Increment rates | |
| ΔpCO2 Group NTr | 1.7 ± 9.0 (0.0; –0.9 to 64.0) |
| Group Tr | 2.0 ± 4.3 (0.4; –0.9 to 19.4) |
| Total | 1.8 ± 8.3 (0.1; –0.9 to 64.0) |
| P | 0.015 |
| ScvO2 Group NTr | –0.11 ± 0.17 (–0.13; –0.53 to 0.46) |
| Group Tr | –0.11 ± 0.18 (–0.06; –0.48 to 0.27) |
| Total | –0.11 ± 0.17 (–0.12; –0.53 to 0.46) |
| P | 0.591 |
| Lactate Group NTr | 1.3 ± 1.2 (0.9; –0.4 to 6.0) |
| Group Tr | 2.3 ± 2.4 (1.6; –0.3 to 10.7) |
| Total | 1.5 ± 1.5 (1.0; –0.4 to 10.7) |
| P | 0.025 |
Data are presented as mean ± SD (median; min–max).